Risperidone
- TRADE NAME: Risperdal (Ortho-McNeil, Janssen); Risperdal Consta (Ortho-McNeil, Janssen)
- INDICATIONS: Schizophrenia, bipolar mania, irritability associated with autistic disorder
- CLASS: Antipsychotic, Mood stabilizer
- HALF-LIFE: 3–30 hours
ACE inhibitors, Alcohol, Alpha blockers, Amantadine, Anesthetics, general, Angiotensin II receptor antagonists, Anxiolytics and hypnotics, Apomorphine, Artemether/Lumefantrine, Barbiturates, Bromocriptine, Cabergoline, Calcium channel blockers, Carbamazepine, Cimetidine, Citalopram, Clozapine, Ethosuximide, Fluoxetine, Histamine, Levodopa, Levodopa, Memantine, Methyldopa, Metoclopramide, Opioid analgesics, Oxcarbazepine, Paliperidone, Paroxetine, Pergolide, Phenytoin, Pramipexole, Primidone, Ranitidine, Ritonavir, Ropinirole, Rotigotine, Sodium Oxybate, Sympathomimetics, Tetrabenazine, Tramadol, Tricyclics, Valproic Acid
PREGNANCY CATEGORY: C
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of patients with dementia-related psychosis.
[C] = Children; [A] = Adults.
Safety and effectiveness have not been established for pediatric patients with schizophrenia <13 years of age, for bipolar mania <10 years of age, and for autistic disorder <5 years of age.
Please login to see the rest of this drug profile
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric